James Flinn - Director IP & Innovation at Immutep :-
"The all-comer result is strong, although the TPS<1% and TPS 1-49% groups are where things are especially interesting.
For the TPS 1-49% group, the ORR reported today was 41.7% compared to 17% for PD-1 monotherapy in historical studies.
Thus 2.5 fold better....
James Flinn - Director IP & Innovation at Immutep :-"The...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.8¢ |
Change
0.008(2.21%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 33.5¢ | $1.782M | 5.096M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 163033 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 226629 | 28 |
View Market Depth
| Last trade - 14.58pm 18/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |